PHARMACOECONOMIC EVALUATION OF ACUTE EXACERBATIONS OF COPD TREATMENT IN A RURAL TERTIARY CARE HSOPITAL

被引:3
作者
Ramanath, K. V. [1 ]
Sabith, Jaseem K. [1 ]
机构
[1] SAC Coll Pharm, Dept Pharm Practice Clin Pharm, Bg Nagar, Karnataka, India
来源
INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH | 2012年 / 3卷 / 04期
关键词
Pharmacoeconomics; Cost of illness; Total direct cost; Total medicine cost Acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD); Total direct medical cost; Total direct non-medical cost;
D O I
10.13040/IJPSR.0975-8232.3(4).1155-60
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: In India because of growing pressure on the healthcare budget, appropriate justification of current expenditures and future investments in public healthcare are becoming a priority. COPD is a major cause of healthcare burden worldwide and it is the one of leading cause of death with increasing the prevalence. Objective: To evaluate the pharmacoeconomic impact of acute COPD exacerbations in a rural tertiary care hospital. Methodology: It is a prospective, observational study conducted in COPD in patients over a period of 9 months. The patients who satisfied the study criteria were enrolled. Results: Over all 50 were enrolled including 42 male and 8 female COPD patients. 60% of patients stayed over a period of 6-10 days in hospital. 4% of patients had a history of duration of illness >10 years. 64% of patients were farmers and only 4% had a monthly income Rs. >10000. 44% had a history of past smoking and 6% were smokers. 34% of patients had co-morbidities with COPD. Minimum total direct medical cost was Rs. 188.79 and maximum was Rs. 9982.12 with a mean +/- SD 2510.51 +/- 1904.11, in which medicine cost was high (mean 1949.21). Minimum total direct non-medical cost was Rs. 10.00 and maximum was Rs. 700.00 with a mean +/- SD 154.16 +/- 166.56, in which travel expenses was high (mean 84.56). Maximum total direct cost was Rs. 10682.12 and minimum was 268.79 with a mean +/- SD 2664.67 +/- 2030.76. Conclusion: This study concluded that, major COPD patients were farmers and they had less monthly income and it was not sufficient for the treatment of acute COPD exacerbations.
引用
收藏
页码:1155 / 1160
页数:6
相关论文
共 12 条
[1]   The costs of exacerbations in chronic obstructive pulmonary disease (COPD) [J].
Andersson, F ;
Borg, S ;
Jansson, SA ;
Jonsson, AC ;
Ericsson, Å ;
Prütz, C ;
Rönmark, E ;
Lundbäck, B .
RESPIRATORY MEDICINE, 2002, 96 (09) :700-708
[2]  
Binai KS, 2011, INDIAN J PHARM PRACT, V4, P13
[3]  
Diaz PT, 2009, APPL THERAPEUTICS CL, p[23, 1]
[4]  
Gibbs KP, 2008, CLIN PHARMACOL THER, P386
[5]   Costs of COPD in Sweden according to disease severity [J].
Jansson, SA ;
Andersson, F ;
Borg, S ;
Ericsson, Å ;
Jönsson, E ;
Lundbäck, B .
CHEST, 2002, 122 (06) :1994-2002
[6]  
Jindal S K, 2004, Indian J Chest Dis Allied Sci, V46, P137
[7]  
Jindal SK, 2006, INDIAN J MED RES, V124, P619
[8]  
Kulkarni U, 2009, AFR J PHARM PHARMACO, V3, P362
[9]  
Mahal DA., DIS BURDEN INDIA EST
[10]   Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD [J].
Miravitlles, M ;
Murio, C ;
Guerrero, T ;
Gisbert, R .
CHEST, 2002, 121 (05) :1449-1455